A new Ivy Brain Tumor Center study finds that recently-approved drug ribociclib may be an important part of treatment for glioblastoma, one of the deadliest cancers in the world.Continue reading
Five years in the making, researchers at ASU are still on the search to find what causes triple negative cancerContinue reading
With a $863,000, three-year grant from the United States Army, Jennifer Barton, director of the BIO5 Institute and professor of biomedical engineering, biosystems engineering,electrical and computer engineering and optical sciences, is continuing her research into a disposable falloposcope to detect early-stage ovarian cancer. A falloposcope is an endoscope used to image the fallopian tubes, where researchers now believe ovarian cancer originates.Continue reading
Don't Forget that Tuesday November 27th is #GivingTuesday. It's a wonderful way to give back this holiday season. Check out these giving opportunities offered by AZBio Members.
‘TGen One Health Collaborative’ uses holistic approach to connect human health and the environmentContinue reading
Carlo Maley, associate professor in the Biodesign Center for Biocomputing, Security and Society and director of the Arizona Cancer Evolution Center, was selected as a recipient of a $10.8M grant from the National Cancer Institute. The Breast Pre-Cancer Atlas will be an active repository for information about breast tumors, open to the scientific community to use for further analysis.Continue reading
INSYS Therapeutics, Inc. (NASDAQ: INSY), announced om November 1, 2018 that a pharmacokinetic (PK) study (INS012-18-119) of its proprietary intranasal naloxone spray formulations for the treatment of opioid overdose showed a distinctive PK profile compared to the current standards of intramuscular (IM) and intravenous (IV) administration of naloxone.
Each Year AZBio extends an opportunity to all member companies to tell us about the veterans on their team. This video is our tribute to them and to all who have served. Continue reading